Case report on asciminib plus ponatinib or axitinib in CML relapse with B lymphoblastic blast crisis
New combo drug stops leukemia that fought back against two drugs
This case report describes a single CML patient who relapsed with B lymphoblastic blast crisis harboring a T315I mutation and a novel e6a3 B…
A new three-drug mix stops a tough leukemia that grew stronger after two drugs failed to control it.
FDA Approves Danziten (nilotinib) for Adult Patients with Newly Diagnosed or Resistant/Intolerant Ph+ CML
The FDA approved a new drug called Danziten for a type of blood cancer called CML.
Danziten (nilotinib) is approved for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)…
The FDA approved Danziten to treat newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia or cases resistant to prior ima…
Imatinib reduces TNF-α levels in CML patients; persistent levels correlate with poor response
Imatinib treatment reduces inflammatory marker in CML patients in small study
A prospective observational cohort of 40 chronic-phase CML patients in India found imatinib significantly reduced serum TNF-α levels from 25…
Dropping inflammation markers in CML patients on imatinib treatment may help doctors predict who will respond well to the drug.
Asciminib superior to IS-TKIs in newly diagnosed CML-CP: MMR 74.1% vs 52.0% at 96 weeks
Could a new leukemia drug work better and cause fewer side effects than current treatments?
In the ASC4FIRST trial, asciminib demonstrated superior efficacy vs investigator-selected TKIs (IS-TKIs) in newly diagnosed CML-CP. At week …
A new leukemia drug helped more patients reach deep disease control with fewer side effects than current standard treatments after two years…